|
C20orf181
|
0.100 |
Biomarker
|
group |
BEFREE |
Potential intravenous tissue plasminogen activator candidates experienced the shortest time to neuroimaging after implementation of a stroke alert system (54 minutes; IQR, 34-66 minutes [n = 13] for intravenous tissue plasminogen activator candidates vs 89.5 minutes; IQR, 62-126.5 minutes [n = 52] for non-intravenous tissue plasminogen activator candidates; P < .01).
|
31704052 |
2020 |
|
C20orf181
|
0.100 |
Biomarker
|
group |
BEFREE |
Following the results of randomized clinical trials supporting the use of mechanical thrombectomy (MT) with tissue plasminogen activator for emergent large vessel occlusion (ELVO), our state Stroke Task Force convened to: update legislation to recognize differences between Primary Stroke Centers (PSCs) and Comprehensive Stroke Centers (CSCs); and update Emergency Medical Services (EMS) protocols to triage direct transport of suspected ELVO patients to CSCs.
|
30530770 |
2020 |
|
C20orf181
|
0.100 |
Biomarker
|
group |
BEFREE |
The aim of this study was to prospectively investigate the occurrence of early poststroke seizures (within 7 days of stroke) in patients undergoing reperfusion therapies (intravenous rtPA [recombinant tissue plasminogen activator] and/or endovascular thrombectomy) in comparison to those not undergoing these procedures.
|
31431399 |
2020 |
|
C20orf181
|
0.100 |
Biomarker
|
group |
BEFREE |
Methods- NINDS rt-PA Study (National Institute for Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator) and SWIFT PRIME trial (Solitaire With the Intention for Thrombectomy as Primary Endovascular Treatment) patients were matched for prognosis (based on age and National Institutes of Health Stroke Scale) and definite/likely anterior circulation large vessel occlusion (based on National Institutes of Health Stroke Scale total score and item pattern), using optimal inverse variance matching, to determine comparative outcomes with nonreperfusion care alone, IVT alone, and IVT+EVT.
|
31311465 |
2019 |
|
C20orf181
|
0.100 |
Biomarker
|
group |
BEFREE |
Tissue plasminogen activator is the only U.S. FDA-approved therapy for ischemic stroke, while there is no specific medication for hemorrhagic stroke.
|
30775405 |
2019 |
|
C20orf181
|
0.100 |
Biomarker
|
group |
BEFREE |
We further found that the expression of Arg-1 was also upregulated in those tPA and RSG-treated stroke mice and the protection against tPA-induced HT and BBB disruption in these mice were abolished in the presence of PPAR-γ antagonist GW9662 (4 mg/kg, 1 hour before dMCAO through intraperitoneal injection).
|
31756041 |
2019 |
|
C20orf181
|
0.100 |
Biomarker
|
group |
BEFREE |
One developed an ICH after receiving tissue plasminogen activator for a cerebrovascular accident after two negative CTs.
|
30336936 |
2019 |
|
C20orf181
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Black individuals and Hispanic individuals are less likely to recognize stroke and call 911 (stroke preparedness), contributing to racial/ethnic disparities in intravenous tissue plasminogen activator use.
|
31260028 |
2019 |
|
C20orf181
|
0.100 |
Biomarker
|
group |
BEFREE |
Minimally invasive surgery procedures, including stereotactic catheter aspiration and clearance of intracerebral hemorrhage (ICH) with recombinant tissue plasminogen activator hold a promise to improve outcome of supratentorial brain hemorrhage, a morbid and disabling type of stroke.
|
30891610 |
2019 |
|
C20orf181
|
0.100 |
Biomarker
|
group |
BEFREE |
Stroke is one of the leading causes of death and disability globally, while intravenous thrombolysis with recombinant tissue plasminogen activator remains the only Food and Drug Administration (FDA)-approved therapy for ischemic stroke.
|
30404981 |
2019 |
|
C20orf181
|
0.100 |
Biomarker
|
group |
BEFREE |
These improvements in outcomes were most strongly associated with process interventions that allocate stroke-specific physical and human resources in the ED, most notably a designated emergency room space for stroke, and with workflows that decrease the time to key checkpoints for determining a patient's eligibility for tPA.
|
31230040 |
2019 |
|
C20orf181
|
0.100 |
Biomarker
|
group |
BEFREE |
The patient was not a candidate for intravenous tissue plasminogen activator because he presented with a wake-up stroke.
|
30060127 |
2019 |
|
C20orf181
|
0.100 |
Biomarker
|
group |
BEFREE |
Although the sample size was small, this study also illustrates the lack of clear efficacy data for optimal treatment strategies, and the ongoing treatment challenges in posterior circulation stroke population in a population of patients outside the rt-PA window.
|
31807387 |
2019 |
|
C20orf181
|
0.100 |
Biomarker
|
group |
BEFREE |
We describe 2 cases of patients with stroke after TAVI who received tPA therapy and mechanical thrombectomy.
|
31327683 |
2019 |
|
C20orf181
|
0.100 |
Biomarker
|
group |
BEFREE |
Awareness of the typical findings, pearls, and pitfalls of CT image interpretation is therefore critical for radiologists, stroke neurologists, and emergency department providers to make accurate and timely decisions regarding both <i>(a)</i> immediate treatment with intravenous tissue plasminogen activator up to 4.5 hours after a stroke at primary stroke centers and <i>(b)</i> transfer of patients with large-vessel occlusion (LVO) at CT angiography to comprehensive stroke centers for endovascular thrombectomy (EVT) up to 24 hours after a stroke.
|
31589578 |
2019 |
|
C20orf181
|
0.100 |
Biomarker
|
group |
BEFREE |
Cumulative 3-year incidences of the co-primary bleeding end points of intracranial hemorrhage, non-intracranial global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO) moderate/severe bleeding, and the primary ischemic end point of ischemic stroke/myocardial infarction were higher in the prior hemorrhagic and ischemic stroke groups than in the no-prior stroke group (6.8%, 2.5%, and 1.3%, <i>P</i><0.0001, 8.8%, 8.0%, and 6.0%, <i>P</i>=0.001, and 12.7%, 13.4%, and 7.5%, <i>P</i><0.0001).
|
31701821 |
2019 |
|
C20orf181
|
0.100 |
Biomarker
|
group |
BEFREE |
Currently, common treatments for stroke might not be optimum if exogenous tPA can pass through the blood-brain barrier and enter the brain, thus adding to the deleterious effects of tPA within the cerebral parenchyma.
|
30552546 |
2019 |
|
C20orf181
|
0.100 |
Biomarker
|
group |
BEFREE |
All groups had similar rates of comorbid disease and tissue plasminogen activator (tPA) administration, and stroke severity did not differ significantly between groups.
|
30925465 |
2019 |
|
C20orf181
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Therefore, treatment with the protease-dead recombinant tPA-S478A holds particular promise as a neurorestorative therapy, as the risk for triggering intracranial hemorrhage is eliminated and tPA-S478A can be delivered intranasally hours after stroke.
|
30996120 |
2019 |
|
C20orf181
|
0.100 |
Biomarker
|
group |
BEFREE |
As the indications of stroke intervention are evolving to further improve stroke care, focus has begun to revolve around recognition of LVO and provision of endovascular thrombectomy with or without the administration of tissue plasminogen activator.
|
31197342 |
2019 |
|
C20orf181
|
0.100 |
AlteredExpression
|
group |
BEFREE |
However, after adjustment for the factors might affect the risk of post-tPA ICH, such as stroke severity, onset-to-treatment time interval, and atrial fibrillation (AF), LDL level was not associated with post-tPA ICH whereas AF was the only significant factor increased the risk of post-tPA ICH (adjusted OR: 1.177, 95% CI 1.080 to 1.283).
|
30367009 |
2019 |
|
C20orf181
|
0.100 |
GeneticVariation
|
group |
BEFREE |
With increasing utilization of intravenous tissue plasminogen activator (t-PA) or thrombectomy to pharmacologically or mechanically remove ischemic stroke causing blood clots, respectively, there is interest in pairing successful cerebrovascular recanalization with neurotherapeutic pharmacological interventions (Fraser et al., J Cereb Blood Flow Metab 37:3531-3543, 2017; Hill et al., Lancet Neurol 11:942-950, 2012; Amaro et al., Stroke 47:2874-2876, 2016).
|
31727174 |
2019 |
|
C20orf181
|
0.100 |
Biomarker
|
group |
BEFREE |
Intravenous Tissue Plasminogen Activator in Stroke Mimics.
|
31412730 |
2019 |
|
C20orf181
|
0.100 |
Biomarker
|
group |
BEFREE |
Besides the inflammation induced by ischemia itself, thrombolytic drug tissue plasminogen activator (tPA) administration could also induce deteriorative inflammation, which is unfavorable for stroke control and recovery.
|
30399590 |
2019 |
|
C20orf181
|
0.100 |
Biomarker
|
group |
BEFREE |
We searched for a predictive model whose volumetric predictions would identify stroke patients who are to benefit from tissue plasminogen activator (t-PA)-induced reperfusion.
|
31283062 |
2019 |